Skip to main content

Home/ health information/ Group items tagged Treatment-For-HIV-1-Infection

Rss Feed Group items tagged

1More

MHRA Approves Cabotegravir: A Game-Changer in HIV Prevention - 0 views

  •  
    In a significant leap forward in the fight against HIV, the Medicines and Healthcare products Regulatory Agency (MHRA) has given the green light to two groundbreaking formulations of cabotegravir. Apretude 30 mg film-coated tablets and Apretude 600 mg prolonged-release suspension for injection are now authorized for preventing sexually transmitted HIV-1 infection in adults and adolescents weighing at least 35kg at increased risk. This approval marks a pivotal moment in HIV (human immunodeficiency virus) prevention, offering an alternative to existing standard pre-exposure prophylaxis or PrEP treatments. HIV, a virus notorious for compromising the immune system, has long been a global health concern. Cabotegravir, a member of the integrase inhibitor group, works by blocking a key enzyme necessary for the replication of HIV-1, thereby reducing the virus's ability to spread.
1More

NICE recommends first long-acting injectable treatment for HIV-1 infection - 0 views

  •  
    In its first, the National Institute for Health and Care Excellence has recommended the use of long-acting injectable treatment for HIV-1 infection in adults, making around 13,000 people eligible for treatment with cabotegravir with rilpivirine in England. The new treatment aims to keep the number of virus particles in the blood so low that it cannot be detected or transmitted between people. Current treatment for HIV‑1 is lifelong antiretroviral tablets taken each day. Use of cabotegravir with rilpivirine is recommended when there is no evidence tosuspect viral resistance, and no previous failure of other anti-HIV-1 medicines. "Clinical trial results show that cabotegravir with rilpivirine is as effective as oralantiretrovirals at keeping the viral load low," NICE stated. Both are administered as two separate injections every two months, after an initial oral (tablet) lead-in period.
1More

TB Is The Leading Cause Of Death Among People living With HIV - 0 views

  •  
    When on TB treatment, people co-infected with #HIV and TB are three times more likely to die from #TB. To reduce these preventable and treatable HIV deaths from TB, you must have access to: Antiretroviral Therapy Regular TB screening TB diagnostics and treatment TB preventive therapy (if no TB symptoms) For More Info Visit Our Website: https://www.drpounders.com/ or Call Us: +1 214-520-8833
1 - 3 of 3
Showing 20 items per page